Related Experiment Video

Updated: Apr 26, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

659

Ceritinib for the treatment of non-small cell lung cancer

L Landi1, F Cappuzzo2

  • 1Medical Oncology Department, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy.

Drugs of Today (Barcelona, Spain : 1998)
|August 8, 2014
PubMed

Insights

Second-generation ALK inhibitor ceritinib shows promise in treating non-small cell lung cancer (NSCLC) that has become resistant to crizotinib. This new drug offers hope for patients who no longer respond to current therapies.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) treatment is increasingly personalized, with anaplastic lymphoma kinase (ALK) rearrangements being a key target.
  • Crizotinib is the standard of care for ALK-positive NSCLC post-chemotherapy, but acquired resistance limits its long-term efficacy.
  • Acquired resistance to ALK inhibitors like crizotinib necessitates the development of novel therapeutic strategies.

Purpose of the Study:

  • To evaluate the potential of ceritinib, a second-generation ALK inhibitor, in overcoming crizotinib resistance in NSCLC.
  • To assess the efficacy of ceritinib against preclinical models of crizotinib-resistant ALK-positive NSCLC.

Main Methods:

  • Preclinical evaluation of ceritinib's antitumor activity.
  • Assessment of ceritinib's potency against ALK-rearranged NSCLC clones resistant to crizotinib.

Main Results:

  • Ceritinib demonstrated significant antitumor activity in preclinical models.
  • The drug showed efficacy against NSCLC clones that had developed resistance to crizotinib.

Conclusions:

  • Ceritinib exhibits potent activity against crizotinib-resistant ALK-positive NSCLC.
  • Ceritinib represents a promising therapeutic option for patients with NSCLC who have developed resistance to crizotinib.
Keywords:
ALK-positive NSCLCAntitumor activityCeritinibLDK-378Non-small cell lung cancer

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.5K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
688
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
611
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K